SW1990Homo sapiens (Human)Cancer cell line
Also known as: SW 1990, SW-1990
Quick Overview
Human pancreatic cancer cell line with metabolic and drug resistance characteristics.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1723 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Pancreas[UBERON:UBERON_0001264] |
Donor Information
| Age | 56 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Pancreatic adenocarcinoma |
|---|---|
| Lineage | Pancreas |
| Subtype | Pancreatic Adenocarcinoma |
| OncoTree Code | PAAD |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000155_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Pro191del (c.569_571CTC[1]) (c.572_574delCTC) | Heterozygous | - | from parent cell line SW1990 |
| MutationSimple | KRAS | p.Gly12Asp (c.35G>A) | Unspecified | - | PubMed=29786757 |
| MutationSimple | FLCN | p.Gln533Ter (c.1597C>T) | Heterozygous | - | from parent cell line SW1990 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine.
Yu Y., Ding F., Gao M., Jia Y.-F., Ren L.
Oncol. Lett. 18:3065-3071(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Differential effector engagement by oncogenic KRAS.";
McCormick F.
Cell Rep. 22:1889-1902(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Resolution of novel pancreatic ductal adenocarcinoma subtypes by global phosphotyrosine profiling.
Biankin A.V., Wu J.-M., Daly R.J.
Mol. Cell. Proteomics 15:2671-2685(2016).
Establishment and characterization of new cell lines of anaplastic pancreatic cancer, which is a rare malignancy: OCUP-A1 and OCUP-A2.
Nishio K., Hasegawa T., Yashiro M., Nakata B., Ohira M., Hirakawa K.
BMC Cancer 16:268.1-268.13(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.
Manning G., Settleman J., Hatzivassiliou G., Evangelista M.
Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.
Linnartz R., Zubel A., Slamon D.J., Finn R.S.
Br. J. Cancer 111:1788-1801(2014).
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Rottapel R., Neel B.G., Moffat J.
Cancer Discov. 2:172-189(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Establish a gemcitabine-resistant pancreatic cancer cell line SW1990/GZ and research the relationship between SW1990/GZ and pancreatic cancer stem cell.
Xu Z.-K., Miao Y.
Zhonghua Wai Ke Za Zhi 48:999-1003(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Identification of SMURF1 as a possible target for 7q21.3-22.1 amplification detected in a pancreatic cancer cell line by in-house array-based comparative genomic hybridization.
Shiratori K., Hirohashi S., Inazawa J., Imoto I.
Cancer Sci. 99:986-994(2008).
Expression and significance of GCS gene in human pancreatic cancer cell SW1990 and its drug-resistant sublines.
Bu G.-B., Zhao Y.-P., Chen G., Zhang T.-P., Li L.-J., Wu Y.-D.
Zhonghua Wai Ke Za Zhi 44:1342-1344(2006).
Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications.
Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.
Oncogene 24:1794-1801(2005).
Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.
Veltman J.A., van Kessel A.G., Hoglund M.
Cancer Res. 64:3052-3059(2004).
Mutations of the BRAF gene in human cancer.";
Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Nature 417:949-954(2002).
Establishment and characterization of human pancreatic adenocarcinoma cell line SW-1990 in tissue culture and the nude mouse.
Sloane N.H., Lepera R.
Cancer Res. 43:4393-4401(1983).